Parkinson’s disease is complex, involving both genetic and environmental factors, including air pollution and other chemical exposures. In particular, pesticide exposure has been…
Read MoreCND Life Sciences (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests…
Read MoreThe molecular processes involved in the development of Parkinson’s disease are not currently known. Emerging…
Read MoreCND Life Sciences, Inc. (CND) announced today that it has raised $13.5 million in its…
Read MoreA link between physical activity and reduced Alzheimer’s and dementia biomarkers is well established, as…
Read MoreAlterity Therapeutics released topline results from its Phase 2 trial of ATH434-201 in patients with…
Read MoreAlthough Parkinson’s disease primarily presents with motor symptoms, other non-motor symptoms, such as depression, anxiety,…
Read MoreIn a clinical proceedings white paper published by the Clinical Neurological Society of America (CNSA)…
Read MoreCognition Therapeutics, Inc. has announced positive results from a Phase 2 trial of CT1812 (zervimesine)…
Read MoreBioVie Inc., a clinical-stage company based in Carson City, Nevada, announced it has fully funded…
Read More
